Parkman Healthcare Partners LLC Invests $23.99 Million in Xenon Pharmaceuticals Inc. $XENE

Parkman Healthcare Partners LLC purchased a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 397,379 shares of the biopharmaceutical company’s stock, valued at approximately $23,986,000. Xenon Pharmaceuticals accounts for approximately 2.5% of Parkman Healthcare Partners LLC’s investment portfolio, making the stock its 11th biggest position. Parkman Healthcare Partners LLC owned 0.41% of Xenon Pharmaceuticals as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Cinctive Capital Management LP lifted its stake in shares of Xenon Pharmaceuticals by 1.1% in the 4th quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company’s stock worth $1,045,000 after acquiring an additional 263 shares during the period. State of Wyoming boosted its holdings in shares of Xenon Pharmaceuticals by 30.4% in the fourth quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 350 shares in the last quarter. Quarry LP increased its stake in shares of Xenon Pharmaceuticals by 25.0% during the third quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 500 shares during the period. Royal Bank of Canada increased its stake in shares of Xenon Pharmaceuticals by 0.7% during the first quarter. Royal Bank of Canada now owns 90,387 shares of the biopharmaceutical company’s stock worth $5,255,000 after acquiring an additional 630 shares during the period. Finally, PNC Financial Services Group Inc. raised its holdings in Xenon Pharmaceuticals by 11.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,574 shares of the biopharmaceutical company’s stock worth $295,000 after purchasing an additional 675 shares in the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Trading Down 0.3%

XENE stock opened at $60.56 on Tuesday. The company’s 50-day moving average price is $62.48 and its 200 day moving average price is $55.92. Xenon Pharmaceuticals Inc. has a 52 week low of $35.60 and a 52 week high of $72.66. The company has a market cap of $5.85 billion, a P/E ratio of -12.78 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.05. During the same quarter in the previous year, the firm earned ($1.07) earnings per share. On average, equities research analysts expect that Xenon Pharmaceuticals Inc. will post -4.73 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on XENE shares. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. Wall Street Zen raised Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Royal Bank Of Canada reduced their price target on Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating for the company in a report on Friday, August 7th. Wells Fargo & Company restated an “overweight” rating and issued a $69.00 price target on shares of Xenon Pharmaceuticals in a research note on Sunday, May 10th. Finally, Needham & Company LLC dropped their price objective on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $77.13.

Insider Buying and Selling

In other Xenon Pharmaceuticals news, Director Gary Patou sold 1,322 shares of the company’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $70,251.08. Following the sale, the director owned 24,896 shares of the company’s stock, valued at approximately $1,322,973.44. This represents a 5.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gillian Cannon sold 1,190 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $63,236.60. Following the completion of the transaction, the director owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. This represents a 44.99% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 12,512 shares of company stock worth $774,088 in the last quarter. Company insiders own 2.91% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.